Trial Profile
Prospective, open-label study of ranibizumab on fibrovascular pigment epithelial detachment (PED) type lesions secondary to age-related macular degeneration
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Nov 2015
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Age-related macular degeneration
- Focus Pharmacodynamics; Therapeutic Use
- 25 Nov 2015 New trial record